Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort

Journal of Clinical Pathology

Volumn 69, Issue 1, 2016, Pages 70-75

  Rocken, Christoph ^a   Behrens, Hans Michael ^a   Boger, Christine ^a   Krüger, Sandra ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; RHOA PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER PATIENT; CENTRAL EUROPEAN; CLINICAL FEATURE; COHORT ANALYSIS; DISTANT METASTASIS; EXON; FEMALE; GENE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PIK3CA GENE; POINT MUTATION; PRIORITY JOURNAL; STOMACH CANCER; TUMOR DIFFERENTIATION; WILD TYPE; ADENOCARCINOMA; ADULT; CAUCASIAN; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; GASTRECTOMY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; STOMACH NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTRECTOMY; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS P21(RAS); REPRODUCIBILITY OF RESULTS; RHOA GTP-BINDING PROTEIN; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953357474     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-202980     Document Type: Article

References (23)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003;362:305-15.
4. Lordick F, Grenacher L, Röcken C, et al. Diagnosis and treatment of gastric cancer. Dtsch Med Wochenschr 2010;135:1671-82.
5. Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
6. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
8. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
9. Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014;46:583-7.
10. Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46:573-82.
11. Ridley AJ. RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microscopy 2013;251:242-9.
12. O'Connor K, Chen M. Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases 2013;4:141-7.
13. Zhou X, Zheng Y. Cell type-specific signaling function of RhoA GTPase: Lessons from mouse gene targeting. J Biol Chem 2013;288:36179-88.
14. Leve F, Morgado-Diaz JA. Rho GTPase signaling in the development of colorectal cancer. J Cell Biochem 2012;113:2549-59.
15. Guan R, Xu X, Chen M, et al. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem 2013;70:613-22.
16. Lauren T. The two histologic main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
17. Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of malignant tumours. 7th edn. Wiley-Blackwell, 2009.
18. Warneke V, Behrens HM, Haag J, et al. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol 2013;22:127-37.
19. Warneke VS, Behrens HM, Böger C, et al. Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors. Ann Oncol 2013;24:725-33.
20. Tan IB, Ivanova T, Lim KH, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011;141:476-85.
21. Chew TW, Liu XJ, Liu L, et al. Crosstalk of Ras and Rho: Activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models. Oncogene 2014;33:2717-27.
22. Konstantinidou G, Ramadori G, Torti F, et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Disc 2013;3:444-57.
23. Makrodouli E, Oikonomou E, Koc M, et al. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: A comparative study. Mol Cancer 2011;10:118.